Atea Pharmaceuticals (AVIR) Insider Berger Sells 29,600 Shares

Franklin Berger recently sold 29,600 shares of AVIR on June 18, 2026. The transaction was not planned, and the shares were sold without a specific price attached. This activity was part of a broader pattern of insider transactions at AVIR on the same day.

Insider Buying and Selling at Atea Pharmaceuticals, Inc.

On June 18, 2026, several insiders at AVIR were active in the market. Howard Berman bought 37,700 shares, while Bruno Lucidi purchased 26,700 shares and sold 29,600 shares. Polly Murphy also sold 29,600 shares. These transactions were not part of any pre-planned trading strategy.

Other Institutional Activity in AVIR

Institutional investors have also been adjusting their positions in AVIR. FMR LLC increased its holdings by 2,271,776 shares, resulting in a total of 11,950,772 shares valued at approximately $64.3 million. BlackRock, Inc. trimmed its position by 55,765 shares, ending with 8,435,437 shares worth about $45.4 million. BML Capital Management reduced its stake by 431,343 shares to hold 7,058,657 shares valued at roughly $37.9 million. Tang Capital Management maintained its holdings at 4,814,700 shares, while Vanguard Capital Management opened a new position with 3,246,124 shares valued at about $17.5 million.

Analysts Set New Price Targets

On March 9, 2026, Evercore ISI Group maintained its 'buy' rating for AVIR with a price target of $10. Morgan Stanley has a 'hold' rating with a $6 target from April 2025, and previously issued a 'sell' rating with a $2 target in June 2024. JP Morgan also maintains a 'hold' rating with an $8 target as of March 2023.

Bottom Line

Franklin Berger's recent sale of AVIR shares is part of a series of insider transactions on June 18, 2026. While insiders are adjusting their positions, institutional investors are making significant moves as well. Analysts have varied opinions on AVIR, with some maintaining positive outlooks despite insider sales. Investors should remember that insider transactions are disclosed after the fact and may not reflect current market conditions.